Introduction
Blood coagulation is initiated in vivo when tissue factor binds Factor VII/VIIa, leading to thrombin generation and platelet activation with the ultimate formation of a fibrin network [1] . This process is regulated by the protein C anticoagulant system. Thrombin binds to thrombomodulin (TM), an integral membrane protein on endothelial cells, and changes its specificity from a pro-coagulant to an anticoagulant enzyme that activates protein C [2, 3] . This process is enhanced by the endothelial protein C receptor in large blood vessels [4] .
Activated protein C (APC) serves as a circulating anticoagulant by inactivating Factors Va
and VIIIa. APC is slowly inactivated in plasma by forming a 1:1 complex with the protein C inhibitor (PCI), a serpin that is the prime inhibitor of APC [5] [6] [7] [8] . The half-life of this complex in the circulation is about 20 minutes in rabbits and 40 minutes in baboons [9, 10] . Due to the activation of protein C by thrombin bound to TM, and the subsequent inactivation of APC by PCI, the concentration of the APC-PCI complex is a sensitive indicator of the degree of activation of blood coagulation. Increased levels of APC-PCI have been observed in hypercoagulation states, or thrombophilia, affecting both the venous and arterial systems; for example, deep vein thrombosis (DVT), pulmonary embolism, disseminated intravascular coagulation and myocardial infarction [11] [12] [13] [14] [15] .
A new sensitive sandwich immunofluorimetric assay for measurements of the APC-PCI complex has been devised [16, 17] . The method employs a monoclonal antibody that is specific for the loop-inserted form of the inhibitor, i.e. PCI that is in complex with APC. Native PCI that is not in complex with APC exists in a 10 4 -fold molar excess over the APC-PCI complex and has no affinity for the antibody. As a reporter antibody a monoclonal antibody against protein C is used.
Resistance to activated protein C is a major risk factor for venous thrombosis that is usually caused by a point-mutation in the gene of coagulation Factor V (FV) [18, 19] .
This mutation, FV Leiden, which renders the FV molecule less susceptible to inactivation by APC, and is the most common hereditary risk factor for venous thromboembolism (VTE) in the Caucasian population and is found in 20-44% of patients with VTE [2] . There is a need for more specific laboratory markers that can be used to predict an elevated risk for recurrent VTE, especially in patients without diagnosed hereditary risk factors for thrombophilia.
We have previously demonstrated higher APC-PCI complex concentrations, indicating increased thrombin generation in carriers of the FV Leiden mutation who were in the recovery phase after finished treatment for VTE [20] . Of the 182 patients in the study, 50
had the FV Leiden mutation while the remaining 132 did not have any known thrombophilic risk factor.
The endothelial cell surface is considered to be the major physiological site for TM function and s-TM is traditionally thought to serve as a marker of endothelial cell damage [21, 22] . It has been confirmed in vitro that s-TM is an early marker of initial endothelial cell membrane changes that are induced by neutrophil derived proteases and oxygen radicals [23] .
Although s-TM might provide some degree of protection against thrombosis due to its proposed anti-inflammatory and anti-coagulant properties, reduced TM on the endothelial cell surface would seriously compromise the anti-thrombotic and anti-inflammatory potential and add to an elevated risk for VTE and VTE recurrence [24, 25] .
The aim of this study was to correlate APC-PCI complex concentrations to thrombomodulin activity (s-TM activity) and thrombomodulin antigen concentrations (s-TM antigen), measured with newly developed assays in the same group of patients [26, 27] . We also report from a prospective follow-up of VTE recurrence after one year.
Materials and methods

Subjects
The patients studied were consecutive patients recruited to the "Malmö Thrombophilia Study" which is a prospective study. patients with prothrombin 20210 mutation, one patient with protein S-deficiency and two patients with lupus anticoagulans were excluded. The subjects comprised 50 patients with FV Leiden and 132 patients without any of the risk factors: G20210A prothrombin mutation, antithrombin deficiency, protein C deficiency protein S deficiency or lupus anticoagulant; Table I ). Venous blood was drawn after informed written consent. It was collected in 5 mL vacuum tubes (Stabilyte®, Trinity Biotech, Bray Ireland) containing citrate with a low pH, which precludes in vitro formation of the APC-PCI complex [28] . The blood was centrifuged at 3600xg for 10 minutes within 30 minutes of collection and the plasma frozen in aliquots at -70º C for later analysis. VTE recurrence was recorded one year after blood-sampling. The study was approved by the Ethics Committee, Lund University.
Methods APC-PCI complex concentration was measured using the previously-described DELFIA assay, which has a functional sensitivity in Stabilyte-plasma of 0.032 µg/L. Using Soluble TM antigen and activity were measured using Stabilyte plasma [26, 27] .
In citrate plasma, the reference interval (mean ±2 SD) for s-TM antigen is 3. 
Results
The APC-PCI complex concentration was higher in VTE patients with FV Leiden than in patients without known thrombophilic risk factors (Table II ; [20] ). There was no difference in D-dimer, s-TM antigen or hsCRP concentrations between the groups, whereas also s-TM activity and the quotient (s-TM activity)/ (s-TM antigen) were both higher in patients with FV Leiden (Table II, Fig. 1 ). For APC-PCI concentration above the 75 th percentile (>0.29 µg/L, defined from the whole study group), the OR for FV Leiden was 3.8
(95% CI 1.9-7.8).
The group of patients without known thrombophilic risk factor had higher APC-PCI complex concentrations than the reference population [28] . There were a number of 
Discussion
The aim of this study was to search for more specific laboratory markers that can be used to predict an elevated risk for VTE and to investigate whether there is an association between APC-PCI complex concentration and s-TM antigen and activity in carriers and non-carriers of the FV Leiden mutation in patients with a previous history of VTE. In addition, in a clinical follow-up after one year we investigated the ability of the methods to predict VTE recurrence. In the whole study group, both carriers and non-carriers of the FV Leiden mutation, correlations were observed between the APC-PCI concentration and D-dimer (r 2 =29%) as well as between APC-PCI concentration and s-TM activity (r 2 =9%) and antigen (r 2 =4%). All these measurements have been suggested as reflecting an on-going prothrombotic state.
We found a higher APC-PCI concentration in VTE patients with FV Leiden than in VTE patients without known risk factor for thrombophilia, indicating an increased thrombin generation and presumably individuals at higher risk for recurrent VTE. In both FV Leiden patients and VTE patients without known risk factor for thrombophilia the APC-PCI method detected a higher degree of hypercoagulability than in healthy individuals. Two earlier case-control studies of patients with previous VTE without thrombophilic defects reported contradictory results, showing either increased or decreased APC levels as a risk factor for thrombosis [29, 30] . In contrast to these methods, we have a very sensitive method that indirectly measures activation of the protein C system and thus in vivo thrombin generation. Increased thrombin generation has been measured recently in patients with recurrent VTE [31] . With that method, no difference in peak thrombin generation was seen between patients with and without FV Leiden, although FV Leiden was detected in more patients with recurrent than without recurrent VTE (38 vs. 27%, p=0.03).
Our results also show that s-TM activity is higher in patients with FV Leiden than in non-carriers, despite the lack of difference between the groups regarding s-TM antigen concentration. The finding regarding s-TM antigen concentration is, however, in disagreement with the results of two previous studies -a small study of children with and without FV Leiden, and a large study of patients suffering from venous thromboembolismboth of which reported that FV Leiden carriers had higher levels of s-TM antigen concentration than patients without this mutation [32, 33] . One explanation for this discrepancy might be the method used to measure antigen concentration. The earlier studies used a commercially available enzyme-linked immunosorbent assay kit (Asserachrom R Thrombomodulin, Diagnostica Stago, France), while we used an in-house enzyme-linked immunosorbent assay. S-TM is present in plasma as fragments of different sizes, and the different results obtained by these two methods might indicate that they measure, at least partly, different fragments. A statistically-significant correlation has been observed between soluble TM antigen levels and soluble TM cofactor activity [26] . This notwithstanding, one possibility is that measurement of s-TM activity is more sensitive than our in-house method of measuring the antigen concentration to changes in plasma concentration of s-TM fragments in this group of patients. If this is true, our measurements of s-TM activity do agree with earlier published results on FV Leiden and s-TM, even though our antigen concentration measurement method was not sensitive enough to detect the small differences between the groups.
It has been suggested that s-TM is degraded from the endothelial cell surface as a consequence of endothelial damage [21] . High concentration and activity of circulating s-TM may imply less TM on the endothelium and an ongoing prothrombotic state for example in patients carrying FV Leiden. On the other hand, a high plasma concentration of s-TM has been associated with a lower risk of developing coronary heart disease, suggesting that s-TM may reflect the level of endothelial expression, at least in patients not carrying TM mutations that affect this expression [24] . The relationship of s-TM antigen concentration and s-TM activity with venous as well as arterial thrombosis is complex, and it remains to be seen whether one or both could be clinically useful.
Although the small sample size limits the possibility for evaluating the ability of the methods to predict VTE recurrence in the different patient groups, an APC-PCI concentration above the 75 th percentile was associated with an OR of 1.9 (95% CI 0.68-5.0) and s-TM activity above the 75 th percentile with an OR of 2.1 (95% CI 0.78-5.8) for VTE recurrence. This is the same order of magnitude as in a recent management study, where a twofold increased risk for recurrent events was observed in patients with elevated D-dimer seven weeks after the end of anticoagulant treatment [34] . In patients without FV Leiden and with VTE recurrence, a significant increase was seen in s-TM activity and the s-TM activity/antigen quotient. The OR for VTE recurrence in patients without FV Leiden and with elevated s-TM activity was 3.6 (95% CI 1.1-12). Since the number of recurrencies is small, our study only indicates that the APC-PCI and the s-TM activity analytes could be sensitive markers of an increased risk for VTE recurrence. In contrast to D-dimer methods, these methods measure well-defined analytes. The patients included in this study are part of a prospective study and we will thus have the opportunity to further evaluate the correlation of the described methods with thrombotic events. Legend to figure 1 Figure 1 Box-plots representing s-TM antigen concentrations and s-TM activity in patients with a previous VTE episode, either with FV Leiden mutation or without known thrombophilic risk factor for VTE. Medians are shown by lines, boxes show first and third quartiles, bars show minimum and maximum values, circles signify outliers, and asterisks represent extreme-values.
